Product Disease Areas
We are focused on the development of IVD products for Autoimmune Diseases, specifically in the areas of:
- Rheumatoid Arthritis (RA)
- Systemic Lupus Erythematosus (SLE)
- Multiple Sclerosis (MS)
- Ankylosing Spondylitis (AS)
- Systemic Sclerosis (SSc)
- Neuromyelitis Optica (NMO)
Therapeutic challenges for autoimmune diseases
Although existing therapies for autoimmune diseases have improved patient treatment over the last decade, many of these drugs have been shown to be active in less than 50% of patients. As autoimmune diseases are chronic conditions, the treatment success or failure is often seen after lengthy treatment cycles, sometimes in excess of 6 months. This is not only expensive to the healthcare provider but also increases the likelihood of those patients developing irreversible tissue and organ damage. Consequently, there is a real need to develop diagnostic solutions that allow clinicians to make better treatment selections for autoimmune diseases, both for current marketed drugs, and for novel drugs in clinical development.
It is widely acknowledged that autoimmune diseases are complex conditions that require sophisticated patient stratification tools to define sub-groups within the population and determine which patients will respond to a certain drug.
Complex conditions require a different approach
The identification of patient subgroups has become essential for developing medicines that target smaller numbers of patients, and work effectively for each individual. In addition, the repositioning of marketed drugs according to response rates or side effects is a key industry initiative that is supported by clinicians, patients and regulatory bodies alike.
At Protagen, our understanding of disease-specific autoantibody profiles and their application to novel, robust diagnostic test development, means that we are exceptionally well positioned to create products which will improve the diagnosis and subsequent treatment of autoimmune disease.